Selective and potent furin inhibitors protect cells from anthrax without significant toxicity

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 6, 2010, Pages 987-995

  Remacle, Albert G ^a   Gawlik, Katarzyna ^a   Golubkov, Vladislav S ^a   Cadwell, Gregory W ^a   Liddington, Robert C ^a   Cieplak, Piotr ^a   Millis, Sherri Z ^a   Desjardins, Roxane ^b   Routhier, Sophie ^b   Yuan, Xue Wen ^b   Neugebauer, Witold A ^b   Day, Robert ^b   Strongin, Alex Y ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Anthrax; Furin; PA83; Peptides; Proprotein convertases; Synthetic small molecule inhibitors

Indexed keywords

CIPROFLOXACIN; FURIN; FURIN INHIBITOR; MATRIX METALLOPROTEINASE 14; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIGEN PRESENTATION; ARTICLE; BACILLUS ANTHRACIS; CARBOXY TERMINAL SEQUENCE; CELL FUNCTION; CELL LINE; CELL PROTECTION; CELL STRAIN MCF 7; CELL SURFACE; CONTROLLED STUDY; DERIVATIZATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CELL LINE, TUMOR; CLONING, MOLECULAR; COMPUTATIONAL BIOLOGY; DROSOPHILA; FURIN; HUMANS; PEPTIDE FRAGMENTS; SUBSTRATE SPECIFICITY;

AVES;

EID: 77953790884     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.02.013     Document Type: Article

References (53)

1. Anderson E.D., Thomas L., Hayflick J.S., Thomas G. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem 1993, 268:24887-24891.
2. Angliker H., Wikstrom P., Shaw E., Brenner C., Fuller R.S. The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 1993, 293:75-81.
3. Basak A., Zhong M., Munzer J.S., Chretien M., Seidah N.G. Implication of the proprotein convertases furin, PC5 and PC7 in the cleavage of surface glycoproteins of Hong Kong, Ebola and respiratory syncytial viruses: a comparative analysis with fluorogenic peptides. Biochem J 2001, 353:537-545.
4. Bassi D.E., Fu J., Lopez de Cicco R., Klein-Szanto A.J. Proprotein convertases: " master switches" in the regulation of tumor growth and progression. Mol Carcinog 2005, 44:151-161.
5. Benjannet S., Savaria D., Laslop A., Munzer J.S., Chretien M., Marcinkiewicz M., et al. Alpha1-antitrypsin Portland inhibits processing of precursors mediated by proprotein convertases primarily within the constitutive secretory pathway. J Biol Chem 1997, 272:26210-26218.
6. Bhattacharjya S., Xu P., Wang P., Osborne M.J., Ni F. Conformational analyses of a partially-folded bioactive prodomain of human furin. Biopolymers 2007, 86:329-344.
7. Bradley K.A., Young J.A. Anthrax toxin receptor proteins. Biochem Pharmacol 2003, 65:309-314.
8. Case D.A., Cheatham T.E., Darden T., Gohlke H., Luo R., Merz K.M., et al. The Amber biomolecular simulation programs. J Comput Chem 2005, 26:1668-1688.
9. Chen J., Lee K.H., Steinhauer D.A., Stevens D.J., Skehel J.J., Wiley D.C. Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformation. Cell 1998, 95:409-417.
10. Chiron M.F., Fryling C.M., FitzGerald D. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 1997, 272:31707-31711.
11. Collier R.J., Young J.A. Anthrax toxin. Annu Rev Cell Dev Biol 2003, 19:45-70.
12. Decha P., Rungrotmongkol T., Intharathep P., Malaisree M., Aruksakunwong O., Laohpongspaisan C., et al. Source of high pathogenicity of an avian influenza virus H5N1: why H5 is better cleaved by furin. Biophys J 2008, 95:128-134.
13. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
14. Feldmann H., Volchkov V.E., Volchkova V.A., Klenk H.D. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis. Arch Virol Suppl 1999, 15:159-169.
15. Fugere M., Day R. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 2005, 26:294-301.
16. Fugere M., Limperis P.C., Beaulieu-Audy V., Gagnon F., Lavigne P., Klarskov K., et al. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 2002, 277:7648-7656.
17. Garten W., Hallenberger S., Ortmann D., Schafer W., Vey M., Angliker H., et al. Processing of viral glycoproteins by the subtilisin-like endoprotease furin and its inhibition by specific peptidylchloroalkylketones. Biochimie 1994, 76:217-225.
18. Gawlik K., Shiryaev S.A., Zhu W., Motamedchaboki K., Desjardins R., Day R., et al. Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site. PLoS ONE 2009, 4:e5031.
19. Gordon V.M., Leppla S.H. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect Immun 1994, 62:333-340.
20. Henrich S., Cameron A., Bourenkov G.P., Kiefersauer R., Huber R., Lindberg I., et al. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003, 10:520-526.
21. Hornak V., Abel R., Okur A., Strockbine B., Roitberg A., Simmerling C. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 2006, 65:712-725.
22. Horton J.D., Cohen J.C., Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007, 32:71-77.
23. Jean F., Stella K., Thomas L., Liu G., Xiang Y., Reason A.J., et al. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 1998, 95:7293-7298.
24. Jiao G.S., Cregar L., Wang J., Millis S.Z., Tang C., O'Malley S., et al. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 2006, 103:19707-19712.
25. Khatib A.M., Siegfried G., Chretien M., Metrakos P., Seidah N.G. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002, 160:1921-1935.
26. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., et al. Clustal W. and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
27. Lazure C. The peptidase zymogen proregions: nature's way of preventing undesired activation and proteolysis. Curr Pharm Des 2002, 8:511-531.
28. Lewis J.H., Iammarino R.M., Spero J.A., Hasiba U., Antithrombin Pittsburgh: an alpha1-antitrypsin variant causing hemorrhagic disease. Blood 1978, 51:129-137.
29. Lopez-Otin C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008, 283:30433-30437.
30. Marti-Renom M.A., Stuart A.C., Fiser A., Sanchez R., Melo F., Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000, 29:291-325.
31. Moulard M., Decroly E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim Biophys Acta 2000, 1469:121-132.
32. Neugebauer W.A., Cote J., Fortier A., Bkaily G., Avedanian L., Jacques D., et al. Sterol peptide conjugates. Understanding Biology Using Peptides, Proceedings of the Nineteenth American Peptide Symposium 2006, vol. 9:120-121.
33. Pasquato A., Pullikotil P., Asselin M.C., Vacatello M., Paolillo L., Ghezzo F., et al. The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J Biol Chem 2006, 281:23471-23481.
34. Pesu M., Watford W.T., Wei L., Xu L., Fuss I., Strober W., et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008, 455:246-250.
35. Radichev I.A., Remacle A.G., Sounni N.E., Shiryaev S.A., Rozanov D.V., Zhu W., et al. Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with ADP/ATP nucleoside transporter (ANT): potential implications linking proteolysis with the energy metabolism in cancer cells. Biochem J 2009, 420:37-47.
36. Remacle A.G., Rozanov D.V., Fugere M., Day R., Strongin A.Y. Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene 2006, 25:5648-5655.
37. Remacle A.G., Shiryaev S.A., Oh E.S., Cieplak P., Srinivasan A., Wei G., et al. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 2008, 283:20897-20906.
38. Rockwell N.C., Krysan D.J., Komiyama T., Fuller R.S. Precursor processing by kex2/furin proteases. Chem Rev 2002, 102:4525-4548.
39. Roebroek A.J., Taylor N.A., Louagie E., Pauli I., Smeijers L., Snellinx A., et al. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 2004, 279:53442-53450.
40. Rott R., Klenk H.D., Nagai Y., Tashiro M. Influenza viruses, cell enzymes, and pathogenicity. Am J Respir Crit Care Med 1995, 152:S16-S19.
41. Rozanov D.V., Deryugina E.I., Ratnikov B.I., Monosov E.Z., Marchenko G.N., Quigley J.P., et al. Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP) The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells. J Biol Chem 2001, 276:25705-25714.
42. Sabet M., Cottam H.B., Guiney D.G. Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages. FEMS Immunol Med Microbiol 2006, 47:369-379.
43. Sarac M.S., Cameron A., Lindberg I. The furin inhibitor hexa-d-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002, 70:7136-7139.
44. Scamuffa N., Calvo F., Chretien M., Seidah N.G., Khatib A.M. Proprotein convertases: lessons from knockouts. FASEB J 2006, 20:1954-1963.
45. Seidah N.G., Mayer G., Zaid A., Rousselet E., Nassoury N., Poirier S., et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008, 40:1111-1125.
46. Shiryaev S.A., Remacle A.G., Ratnikov B.I., Nelson N.A., Savinov A.Y., Wei G., et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 2007, 282:20847-20853.
47. Stadler K., Allison S.L., Schalich J., Heinz F.X. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol 1997, 71:8475-8481.
48. Stieneke-Grober A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992, 11:2407-2414.
49. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002, 3:753-766.
50. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu Rev Biochem 1983, 52:655-709.
51. Wu C.C., Hayashi T., Takabayashi K., Sabet M., Smee D.F., Guiney D.D., et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 2007, 104:3990-3995.
52. Ye Y., Godzik A. Flexible structure alignment by chaining aligned fragment pairs allowing twists. Bioinformatics 2003, 19:246-255.
53. Zambon M.C. The pathogenesis of influenza in humans. Rev Med Virol 2001, 11:227-241.